期刊文献+

普罗布考对脑梗死患者急性期血清MMP-9水平的影响 被引量:10

Effect of probucol on the level of MMP-9 in acute stage of cerebral infarction
原文传递
导出
摘要 目的观察普罗布考对脑梗死患者急性期血清基质金属蛋白酶9(matrix metalloproteinases9,MMP-9)水平的影响。方法采用自身对照和组间对照,将62例急性期脑梗死患者分为2组,其中普罗布考组(32例),常规治疗组(30例),用酶谱法分别测定治疗前后血清MMP-9水平的变化。结果(1)普罗布考组治疗2周后血清MMP-9水平较治疗前明显降低(P<0.05),而常规治疗组治疗前后血清MMP-9水平无明显差异(P>0.05);(2)治疗2周后普罗布考组血清MMP-9水平较常规治疗组明显降低(P<0.05)。结论普罗布考能降低脑梗死患者急性期血清MMP-9水平,可能因此抑制了血-脑屏障的早期开放和脑水肿,从而减轻缺血性脑损伤,防止脑梗死出血转化和再发。 Objective To observe the effect of probucol on the level of MMP-9 in acute stage of cerebral infarction. Methods Using a random and single blind control test, 62 patients with cerebral infarction in acute stage were assigned into probucol group (n = 32) and control group (n = 30). With the method of SDS-Page zymograph, the levels of MMP-9 in serum were measured before and after therapy. Results ( 1 ) After 2 weeks of follow-up, the level of MMP-9 in serum was lower (P〈0. 05) in the probucol group than that in control group. (2) The level of MMP-9 in serum was lower (P〈0. 05) in the probucol group than that in control group after two-week therapy. Conclusions Probucol can reduce the level of MMP-9 in acute stage of cerebral infarction, thus may relieve the ischemic brain injury.
出处 《卒中与神经疾病》 2008年第2期89-91,共3页 Stroke and Nervous Diseases
关键词 普罗布考 脑梗死 基质金属蛋白酶9 Probucol Cerebral infarction MMP-9
  • 相关文献

参考文献7

二级参考文献32

  • 1刘建平.非随机研究的系统评价方法(一)[J].中国循证医学,2001,1(4):239-243. 被引量:73
  • 2[1]Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation, 2002, 105 (16): 2 000-004
  • 3[2]Brasen JH, Harsch M, Niendorf A. Survival and cardiovascular pathology of hetero-zygous watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol(0.03%)-enriched diet. Virchows Arch, 1998, 432 (6): 557-562
  • 4[3]Brasen JH, Harsch M, Niendorf A. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits. Virchows Arch, 1995, 426 (2):179-188
  • 5[4]Xu XP, Meisel SR, Ong JM. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human moncyte-derived macrophages. Circulation, 1999, 99: 993-998
  • 6[6]Crisby M, Nordin-Fredriksson G, Shah PK. Pravastatin treatment increases collagen content and decreases lipid content, inflammation,metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 2001, 103: 926-933
  • 7[7]Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol, 2001, 88: 3J-6J
  • 8[8]Loftus IM, Naylor AR, Goodall S. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke, 2000, 31 (1): 40-47
  • 9[10]Kanaki T, Saito Y. Anti-atherogenic drugs. Nippon Rinsho, 1998, 56 (10): 2 635-639
  • 10del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab, 2003, 23 (8) : 879.

共引文献85

同被引文献116

引证文献10

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部